Daligdig, Chantel .

HRN: 15-54-50  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/21/2023
CEFUROXIME 750MG (VIAL)
05/21/2023
05/28/2023
IV
340mg
Q8
PCAP C
Waiting Final Action 
05/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/21/2023
05/25/2023
IV
150mg
Q24
PCAP C
Waiting Final Action 
05/24/2023
CEFTRIAXONE 1G (VIAL)
05/24/2023
05/31/2023
IVT
1000mg
Q24
PCAP C
Waiting Final Action 
05/25/2023
CEFUROXIME 750MG (VIAL)
05/25/2023
05/29/2023
IVT
340mg
Q8
PCAP
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: